A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary)
- Indications Sickle cell anaemia; Vascular disorders
- Focus Therapeutic Use
- Acronyms HESTIA3
- Sponsors AstraZeneca
- 25 Nov 2019 Planned End Date changed from 9 Nov 2020 to 20 Oct 2020.
- 25 Nov 2019 Planned primary completion date changed from 9 Nov 2020 to 20 Oct 2020.
- 25 Nov 2019 Status changed from recruiting to active, no longer recruiting.